Product Details:

• Drug Type Specific Drug
• Ingredients ABIRATERONE 250
• Physical Form Tablets
• Function Cancer Treatment
• Dosage Prostate Cancer Metastatic castration-resistant prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic castration-resistant prostate cancer (CRPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Yonsa Indicated in combination with methylprednisolone for the treatment of patients with metastatic CRPC 500 mg (four 125-mg tablets) PO qDay in combination with methylprednisolone 4 mg PO BID Metastatic high-risk castration-sensitive prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic high-risk castration-sensitive prostate cancer (CSPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Dosage Modifications Strong CYP3A4 inducers Coadministration with strong CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital): Avoid if possible; if strong CYP3A4 inducer must be administered, increase abiraterone dosage frequency of abiraterone Reduce dose back to the previous dose and frequency, if the concomitant strong CYP3A4 inducer is discontinued Yonsa Increase from 500 mg qDay to 500 mg BID Zytiga Increase from 1000 mg qDay to 1000 mg BID Hepatic impairment (Zytiga) Baseline LFTs Mild (Child-Pugh A): No dosage adjustment necessary Moderate (Child-Pugh B): Reduce starting dose to 250 mg PO qDay; monitor ALT, AST, and bilirubin prior to start of treatment, qWeek for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment, discontinue abiraterone and do not retreat patients Severe (Child-Pugh C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN: Interrupt treatment; reinitiate at reduced dose of 750 mg PO qDay following return of LFTs to baseline or to AST/ALT 2.5x ULN and total bilirubin 1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs at 750 mg/day, may restart at 500 mg/day (after LFTs decrease as above) If hepatoxicity recurs at reduced dose of 500 mg/day, discontinue treatment Permanently discontinue treatment for patients who develop a concurrent elevation of ALT >3x ULN and total bilirubin >2x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation Hepatic impairment (Yonsa) Baseline Moderate (Child-Pugh Class B): Reduce 125 mg PO qDay; monitor ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment: Discontinue treatment and do not retreat patients with abiraterone Severe (Child-Pugh Class C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN): Interrupt treatment; restart at a reduced dose of 375 mg qDay following return of liver function tests to the patients baseline or to AST and ALT 2.5x ULN and total bilirubin 1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs on 375 mg/day, may be restart aeduced dose of 250 mg/day (after LFTs decrease as above) I
• Suitable For Aged Person, Adults
• Quantity 5 Boxes
• Supply Ability : 50 Bottle Per Day
• Share Your Product: